In mice transplanted with JeKo mantle cell lymphoma cells, co-administration of CAR-T cell engager and CD19-CAR-T cells successfully eliminates both CD19+ and CD19- lymphoma cells and prevent antigen-negative relapse. This evidence concerns the gene CD19 and mantle cell lymphoma.